---
title: CRO Daily News — October 8, 2026
slug: daily-news-2026-10-08-cro
site: cro
post_kind: news
byline: BioBM
description: October 8 CRO daily: Marvel Biosciences Engages Novotech for Phase 1 First-in-Human Trial of MB-204 in Australia — Novotech's engagement demonstrates…
canonical_url: https://www.cro.directory/posts/daily-news-2026-10-08-cro
published_at: 2026-10-08T23:59:46.667Z
last_updated: 2026-10-09T00:00:17.848Z
---

### Marvel Biosciences Engages [Novotech](/companies/novotech-cro) for Phase 1 First-in-Human Trial of MB-204 in Australia
- Marvel Biosciences signed a Letter of Intent with [Novotech](/companies/novotech-cro) to conduct a Phase 1 SAD/MAD study of MB-204, a novel adenosine A2a antagonist for autism spectrum disorder and related neurodevelopmental disorders.
- Novotech will provide end-to-end clinical trial management including site selection, regulatory submissions, biostatistics, data management, and medical writing, with the SAD study expected to initiate in Q4 2026 in Australia.
- Australia's streamlined regulatory environment and 43.5% R&D tax credit on qualifying expenditures make it an attractive jurisdiction for Marvel's transition from preclinical to clinical-stage development.

**Operational Impact**

[Novotech](/companies/novotech-cro)'s engagement demonstrates continued demand for Asia-Pacific first-in-human CRO services among early-stage biotech sponsors seeking to combine regulatory efficiency with cost containment through Australia's tax credit framework.

*Source: [PharmaSource RSS](https://pharmasource.global/content/news/cro-news/marvel-biosciences-signs-loi-with-novotech-cro-for-phase-1-first-in-human-trial-of-mb-204-in-australia)*

## References

1. [PharmaSource RSS — Marvel Biosciences Engages Novotech for Phase 1 First-in-Human Trial of MB-204 in Australia](https://pharmasource.global/content/news/cro-news/marvel-biosciences-signs-loi-with-novotech-cro-for-phase-1-first-in-human-trial-of-mb-204-in-australia)

Source: https://www.cro.directory/posts/daily-news-2026-10-08-cro